ISRCTN64926597进行中（未招募）未知
Multiple Interventions of Diabetic Foot Ulcer Treatment trial
The Leeds Teaching Hospitals NHS Trust0 个研究点目标入组 213 人开始时间: 2017年6月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 213
研究概览
简要总结
2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32312727/ (added 19/10/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 15/02/2022:
- •1. Aged =18 years
- •2. Diagnosis of Diabetes Mellitus (according to WHO criteria)
- •3. Has a chronic DFU or surgical debridement wound or open minor amputation and in the opinion of the attending clinical team is not on a healing trajectory despite usual best care for a minimum of 4 weeks since initial presentation at the MDT DFU service*
- •4.1 Ankle brachial index for the leg of the index ulcer =0.7 or non-compressible (measurements available in the participants notes taken within 3 months of randomisation can be used if no change in intervention or vascular events have occurred), OR
- •4.2 Toe brachial index =0.5 or opening toe pressure =50mmHg or non-compressible
- •5. Expected to comply with the treatment strategies and follow up schedule
- •6. Consent to foot and wound photography
- •7. Consent to participate (written/witnessed verbal informed consent)
- •*Defined as failure to achieve >50% reduction in index ulcer area over a minimum of 4 weeks using local wound measurement policies
- •Previous inclusion criteria as of 10/12/2019:
- •1. Aged =18 years
- •2. Diagnosis of Diabetes Mellitus (according to WHO criteria)
- •3. Has a chronic DFU or surgical debridement wound or open minor amputation and in the opinion of the attending clinical team is not on a healing trajectory despite usual best care for a minimum of 4 weeks since initial presentation at the MDT DFU service*
- •4. Ankle brachial index for the leg of the index ulcer =0.7 or non-compressible (measurements available in the participants notes taken within 3 months of randomisation can be used if no change in intervention or vascular events have occurred)
- •5. Expected to comply with the treatment strategies and follow up schedule
- •6. Consent to foot and wound photography
- •7. Consent to participate (written/witnessed verbal informed consent)
- •*Defined as failure to achieve >50% reduction in index ulcer area over a minimum of 4 weeks using local wound measurement policies
- •Previous inclusion criteria as of 22/11/2018:
- •1. Aged =18 years
- •2. Diagnosis of Diabetes Mellitus (according to WHO criteria)
- •3. Has a chronic DFU or surgical debridement wound or open minor amputation defined by either (a) OR (b) below:
- •3(a). Duration of = 12 weeks since initial presentation at the MDT DFU clinic and in the opinion of the attending clinical team is considered not to be on a healing trajectory despite usual best care†
- •3(b). Having <50% reduction in index ulcer area during a minimum period of 4 weeks prior to randomisation*
- •4. The index DFU has an area =0.8cm2
- •5. Ankle brachial index for the leg of the index ulcer =0.7 or non-compressible (measurements available in the participants notes taken within 3 months of randomisation can be used if no change in intervention or vascular events have occurred)
- •6. Expected to comply with the treatment strategies and follow up schedule
- •7. Consent to foot and wound photography
- •8. Consent to participate (written/witnessed verbal inf
排除标准
- •Current exclusion criteria as of 15/09/2017:
- •1. Has any current clinically infected DFU on the foot of the index ulcer (as per IDSA guidelines)
- •2. HbA1C> 110mmol/mol (measurements available in the participants notes taken within 3 months of randomisation can be used if no change in intervention or vascular events have occurred)
- •3. Estimated glomerular filtration rate (eGFR) < 20mL/min/1.73m2
- •4. Index ulcer duration > 2 years (measurements taken within 3 months of randomisation can be used if no change in intervention or vascular events have occurred)
- •5. Planned or previous treatment with corticosteroids to an equivalent dose of prednisolone > 10mg per day or other immunosuppressive/immunomodulating therapy within 4 weeks prior to randomisation
- •6. Has evidence of connective tissue disorders as a cause of ulceration (e.g. vasculitis or rheumatoid arthritis)
- •7. Has evidence of dermatological disorders as a cause of ulceration (e.g. pyoderma gangrenosum or epidermolysis bullosa)
- •8. Planned or previous growth factor treatment within 4 weeks prior to randomisation
- •9. Planned or previous revascularisation or foot surgery affecting healing within the 4 weeks prior to randomisation
- •10. Index ulcer base has bone or joint involvement
- •11. Previously received DCD for the index ulcer within 4 weeks prior to randomisation
- •12. Previously received NPWT for the index ulcer within 4 weeks prior to randomisation
- •13. Previously received hydrosurgical or surgical debridement for the index ulcer within 4 weeks prior to randomisation
- •14. Has previously been randomised to the MIDFUT study
- •15. Unable to receive one or more of the randomised treatment strategies for any reason at the discretion of the attending clinical team (e.g. risk of excessive bleeding, serious falls risk, known allergies to NPWT dressings or dCELL dermis preparation components)
- •Previous exclusion criteria:
- •1. Has any current clinically infected DFU (as per IDSA guidelines)
- •2. HbA1C> 110mmol/mol
- •3. Estimated glomerular filtration rate (eGFR) < 20mL/min/1.73m2
- •4. Index ulcer duration > 2 years
- •5. Planned or previous treatment with corticosteroids to an equivalent dose of prednisolone > 10mg per day or other immunosuppressive therapy within 4 weeks prior to randomisation
- •6. Has evidence of connective tissue disorders (e.g. vasculitis or rheumatoid arthritis) and has planned or is under active treatment
- •7. Has evidence of dermatological disorders as a cause of ulceration (e.g. pyoderma gangrenosum or epidermolysis bullosa)
- •8. Planned or previous growth factor treatment within 4 weeks prior to randomisation
- •9. Planned or previous revascularisation or foot surgery affecting healing within the 4 weeks prior to randomisation
- •10. Index ulcer base has bone or joint involvement
- •11. Previously received DCD for the index ulcer within 4 weeks prior to randomisation
- •12. Previously received NPWT for the index ulcer within 4 weeks prior to randomisation
- •13. Previously received hydrosurgical or surgical debridement for the index ulce
研究者
相似试验
已完成
2 期
A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot UlcersDiabetic Foot UlcerNCT00915486Kuros Biosurgery AG211
已完成
早期 1 期
Placenta Derived Stem Cells for Treating of Chronic Ulcers and NeuropathyDiabetic NeuropathiesDiabetic Foot UlcerDiabetic FootNCT06373809Michael H Carstens20
已完成
不适用
UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue RepositoryDiabetic Foot UlcersOsteomyelitisNCT02463500University of Texas Southwestern Medical Center70
进行中（未招募）
不适用
REDUCE Trial: Reducing the impact of diabetic foot ulcers (DFUs)Diabetic foot ulcersNutritional, Metabolic, EndocrineDiabetes mellitusISRCTN15570706niversity Hospitals of Derby and Burton NHS Foundation Trust559
撤回
不适用
Developing a Diabetic Foot Ulcer ProtocolDiabetic Foot UlcersNCT01068171The University of Texas Health Science Center, Houston